Skip to main content
2025 AABB Annual Meeting Main banner
Final Program


Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Event Icons
Assessor Sessions
Assessor Sessions
Committee Meetings
Committee Meetings
Foundation Events
Foundation Events
Networking Events
Networking Events
Oral Abstracts
Oral Abstracts
CABP Eligible
CABP Eligible

Science & Innovation Theater presented by Sanofi

Sunday, October 26, 2025
1:15 PM - 2:15 PM  PT
Room: SDCC Exhibit Hall F-H
CE: N/A

Sponsored By 

    Speaker(s)

  • Jay S. Raval, MD

    Professor, Department. of Pathology and Laboratory Medicine
    University of Vermont Medical Center
    Burlington, Vermont

    Disclosure(s): Medtronics: Consultant/Advisory Board (Ongoing), Honoraria (Ongoing); Sanofi: Consultant/Advisory Board (Ongoing), Honoraria (Ongoing), Speaker's Bureau (Ongoing); Terumo BCT: Consultant/Advisory Board (Ongoing)

Early Initiation Matters: Latest Data and Real-world Evidence with CABLIVI®(caplacizumab-yhdp)

Timely diagnosis and treatment initiation are crucial in the management of acquired thrombotic thrombocytopenic purpura (aTTP/iTTP). This session will examine the latest findings and real-world evidence demonstrating the benefits of early treatment initiation with CABLIVI (caplacizumab-yhdp). Dr. Raval will discuss how early therapeutic strategies influence patient outcomes, review the Capla1000+ Project, and highlight Healthcare Resource Utilization data. Attendees will leave with practical insights into optimizing treatment timing and improving care for patients with aTTP/iTTP.